Moreover, the crucial role of STAT3 blockage in mediating HME’s anti-bladder cancer action was confirmed by the abrogation of HME-elicited cytotoxicity when HME failed to mitigate STAT3 activation (Figure 3C,D). The gene discussed is STAT3; the disease is urinary bladder carcinoma.